» Articles » PMID: 29506506

Cancer Stem Cells As Key Drivers of Tumour Progression

Overview
Journal J Biomed Sci
Publisher Biomed Central
Specialty Biology
Date 2018 Mar 7
PMID 29506506
Citations 393
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cancer stem cells (CSCs) are subpopulations of cancer cells sharing similar characteristics as normal stem or progenitor cells such as self-renewal ability and multi-lineage differentiation to drive tumour growth and heterogeneity. Throughout the cancer progression, CSC can further be induced from differentiated cancer cells via the adaptation and cross-talks with the tumour microenvironment as well as a response from therapeutic pressures, therefore contributes to their heterogeneous phenotypes. Challengingly, conventional cancer treatments target the bulk of the tumour and are unable to target CSCs due to their highly resistance nature, leading to metastasis and tumour recurrence.

Main Body: This review highlights the roles of CSCs in tumour initiation, progression and metastasis with a focus on the cellular and molecular regulators that influence their phenotypical changes and behaviours in the different stages of cancer progression. We delineate the cross-talks between CSCs with the tumour microenvironment that support their intrinsic properties including survival, stemness, quiescence and their cellular and molecular adaptation in response to therapeutic pressure. An insight into the distinct roles of CSCs in promoting angiogenesis and metastasis has been captured based on in vitro and in vivo evidences.

Conclusion: Given dynamic cellular events along the cancer progression and contributions of resistance nature by CSCs, understanding their molecular and cellular regulatory mechanism in a heterogeneous nature, provides significant cornerstone for the development of CSC-specific therapeutics.

Citing Articles

Precise targeting of transcriptional co-activators YAP/TAZ annihilates chemoresistant brCSCs by alteration of their mitochondrial homeostasis.

Talukdar P, Pramanik K, Gatti P, Mukherjee P, Ghosh D, Roy H Signal Transduct Target Ther. 2025; 10(1):61.

PMID: 39979255 PMC: 11842803. DOI: 10.1038/s41392-025-02133-x.


Relationship between transmembrane emp24 domain containing 2 expression and tumor stem cell characteristics in oral cancer.

Wu Y, Zhang S, Zou G Cytojournal. 2025; 22:5.

PMID: 39958879 PMC: 11829313. DOI: 10.25259/Cytojournal_132_2024.


Cellular and Molecular Mechanisms Modulated by Genistein in Cancer.

Naponelli V, Piscazzi A, Mangieri D Int J Mol Sci. 2025; 26(3).

PMID: 39940882 PMC: 11818640. DOI: 10.3390/ijms26031114.


Quinalizarin induces autophagy, apoptosis and mitotic catastrophe in cervical and prostate cancer cells.

Trybus W, Trybus E, Obarzanowski M, Krol T Sci Rep. 2025; 15(1):5252.

PMID: 39939343 PMC: 11822151. DOI: 10.1038/s41598-025-89847-8.


Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.

PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.


References
1.
Levental K, Yu H, Kass L, Lakins J, Egeblad M, Erler J . Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5):891-906. PMC: 2788004. DOI: 10.1016/j.cell.2009.10.027. View

2.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

3.
Kobayashi A, Okuda H, Xing F, Pandey P, Watabe M, Hirota S . Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011; 208(13):2641-55. PMC: 3244043. DOI: 10.1084/jem.20110840. View

4.
Giancotti F . Mechanisms governing metastatic dormancy and reactivation. Cell. 2013; 155(4):750-64. PMC: 4354734. DOI: 10.1016/j.cell.2013.10.029. View

5.
Lee G, Hall 3rd R, Ahmed A . Cancer Stem Cells: Cellular Plasticity, Niche, and its Clinical Relevance. J Stem Cell Res Ther. 2016; 6(10). PMC: 5123595. DOI: 10.4172/2157-7633.1000363. View